Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 2/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.40 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.38 |
| ▸ | CPS1 | P31327 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12883118 | 0.86 | PDE2A (0.42) | KMT2APTGS1PTGS2PDE2APOLB | |
| SCHEMBL28790628 | 0.83 | PDE2A (0.41) | PTGS1PTGS2PDE2ACARM1 | |
| SCHEMBL31063437 | 0.82 | CA12 (0.45) | KMT2APTGS1PTGS2MAOBPDE2A | |
| SCHEMBL8241491 | 0.82 | CA12 (0.45) | KMT2APTGS1PTGS2MAOBPDE2A | |
| SCHEMBL30829775 | 0.81 | ALDH1A1 (0.47) | ALDH1A1KMT2AMAOBPARP10BRD4 | |
| SCHEMBL1020456 | 0.81 | ALDH1A1 (0.47) | ALDH1A1KMT2AMAOBPARP10BRD4 | |
| SCHEMBL12889913 | 0.81 | ALDH1A1 (0.47) | ALDH1A1KMT2APARP10BRD4BRPF1 | |
| SCHEMBL8589302 | 0.80 | PTGS2 (0.63) | ALDH1A1KMT2APTGS1PTGS2PARP10 | |
| SCHEMBL9946003 | 0.79 | TDP1 (0.54) | ALDH1A1KMT2APARP10BRD4BRPF1 | |
| SCHEMBL18119645 | 0.78 | NQO1 (0.48) | ALDH1A1KMT2APTGS2PDE2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11634425-B2 | Pharmaceutical compounds | PFIZER INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-20220162197-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | Epizyme, Inc. | 2022-05-26 | — | — | US | disclosed |
| WO-2022026823-A1 | CDK19-SELECTIVE INHIBITORS, AND METHODS OF USE THEREOF | CHAN ZUCKERBERG BIOHUB, INC. (US) | 2022-02-03 | — | — | WO | disclosed |
| WO-2021032992-A1 | PHARMACEUTICAL COMPOUNDS | ReViral Limited (GB) | 2021-02-25 | — | — | WO | disclosed |
| US-10882863-B2 | Compounds for reducing c-Myc in c-Myc overexpressing cancers background | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-01-05 | — | — | US | disclosed |
| US-10385070-B2 | Chroman-spirocyclic piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-08-20 | — | — | US | disclosed |
| US-20190194212-A1 | Compounds For Reducing c-Myc In c-Myc Overexpressing Cancers Background | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2019-06-27 | — | — | US | disclosed |
| US-10233191-B2 | Fused piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-03-19 | — | — | US | disclosed |
| US-20190070183-A1 | Targeting Casein Kinase-1 and PI3K/AKT/mTOR Pathways for Treatment of c-Myc-Overexpressing Cancers, Organ Transplant Associated Complications and Autoimmune Diseases | UNIV COLUMBIA (US) | 2019-03-07 | — | — | US | disclosed |
| US-9796716-B2 | Selective inhibitors of Tec and Src protein kinase families | PHARMASCIENCE, INC. (CA) | 2017-10-24 | — | — | US | disclosed |
| US-8673925-B1 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20120264749-A1 | MORPHOLINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-10-18 | — | — | US | disclosed |
| US-20120264749-A1 | MORPHOLINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-10-18 | — | — | US | disclosed |
| US-20120245136-A1 | CHROMAN-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-09-27 | — | — | US | disclosed |
| US-20120196869-A1 | PYRROLOPYRAZINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-08-02 | — | — | US | disclosed |
| US-8178490-B2 | Polybasic bacterial efflux pump inhibitors and therapeutic uses thereof | REMPEX PHARMACEUTICALS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178490-B2 | Polybasic bacterial efflux pump inhibitors and therapeutic uses thereof | REMPEX PHARMACEUTICALS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20110306607-A1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-12-15 | — | — | US | disclosed |
| US-20100152098-A1 | POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | MPEX PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100152098-A1 | POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | MPEX PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162197-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | EP300, KAT2A, KAT6A | ALDH1A1 2786/4885KMT2A 33/4885PTGS1 4366/4885 |
| US-20190194212-A1 | Compounds For Reducing c-Myc In c-Myc Overexpressing Cancers Background | MYC, MYCBP, BCOR | ALDH1A1 3356/4885KMT2A 531/4885PTGS1 3937/4885 |
| US-10233191-B2 | Fused piperidine amides as modulators of ion channels | TRPV1, TRPA1, KCNJ2 | ALDH1A1 2307/4885KMT2A 1347/4885PTGS1 434/4885 |
| US-20100152098-A1 | POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | ABCB11, ABCB1, SLC47A1 | ALDH1A1 4062/4885KMT2A 3928/4885PTGS1 1965/4885 |
| US-20110306607-A1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | KCNJ2, TRPV1, KCNJ1 | ALDH1A1 1614/4885KMT2A 2425/4885PTGS1 1061/4885 |
| US-20190070183-A1 | Targeting Casein Kinase-1 and PI3K/AKT/mTOR Pathways for Treatment of c-Myc-Overexpressing Cancers, Organ Transplant Associated Complications and Autoimmune Diseases | MYC, MTOR, MALT1 | ALDH1A1 4822/4885KMT2A 1025/4885PTGS1 3251/4885 |
| US-20120245136-A1 | CHROMAN-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | KCNJ2, KCNJ1, KCNC1 | ALDH1A1 1764/4885KMT2A 2130/4885PTGS1 1600/4885 |
| US-20120196869-A1 | PYRROLOPYRAZINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | KCNJ2, KCNJ5, KCNJ1 | ALDH1A1 1663/4885KMT2A 2577/4885PTGS1 1149/4885 |
| US-20120264749-A1 | MORPHOLINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | KCNJ2, TRPM5, KCNQ1 | ALDH1A1 1738/4885KMT2A 1876/4885PTGS1 1875/4885 |
| US-11634425-B2 | Pharmaceutical compounds | GABRA6, CHRNA6, CNR1 | ALDH1A1 3010/4885KMT2A 3408/4885PTGS1 3543/4885 |
| US-10882863-B2 | Compounds for reducing c-Myc in c-Myc overexpressing cancers background | MYC, MYCBP, BCOR | ALDH1A1 3444/4885KMT2A 548/4885PTGS1 3965/4885 |
| US-10385070-B2 | Chroman-spirocyclic piperidine amides as modulators of ion channels | KCNJ2, KCNJ1, KCNC1 | ALDH1A1 1764/4885KMT2A 2130/4885PTGS1 1600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.